Harbin, China, Sept. 9, 2011 /PRNewswire-Asia-FirstCall/ --
China Sky One Medical, Inc. ("China Sky One Medical" or "the
Company") (NASDAQ: CSKI), a leading fully integrated pharmaceutical
company in the People's Republic of
China ("PRC"), today announced that Mr. Stanley Hao resigned from his positions as Vice
President, Secretary and Director of the Company and Ms. Xiao-yan
Han resigned from her positions of Vice Chairman and Director of
the Company effective as of September 5th,
2011. Mr. Hao's and Ms. Han's resignations were for personal
reasons and were not as a result of any disagreement with the
Company on any matter relating to its operations, policies or
practices.
In addition, on September 5, 2011,
the Company's Board of Directors appointed Mr. Jian-ping Li and Mr.
Wen-chao Zhang as Directors to fill the vacancies resulting from
the resignations by Mr. Hao and Ms. Han. Ms. Bing Liu was appointed
as the new Board Secretary.
In March of 2010, Mr. Jian-ping Li joined the Company as general
manager in charge of the Company's manufacturing facilities. Prior
to joining the Company, he worked as technologist at Harbin
Pharmaceutical Group from March 1990
to May 1994; from January 1995 to November
1997 he worked at Heilongjiang Kangxin Pharmaceutical
Company as factory managing director assistant; from January 1998 to August
2006, he worked at Longgui Pharmacuetical Company as Chief
Executive Officer. Mr. Li graduated from China Pharmaceutical
University in 1990 with a Bachelor's Degree in chemistry, and from
Jilin University in 2010 with a
Master's Degree in bio-pharmaceuticals.
In March of 2006, Mr. Wen-chao Zhang joined the Company as the
chief engineer at the Company's research department. Prior to
joining the Company, he was chief engineer at Global Green
Technology Group from July 2003 to
September 2005, and was project
manager at Pavay Gene Pharmaceutical Company from February 2001 to May
2003. Mr. Zhang graduated from China Southern University of Technology in 2001 with a
Doctorate degree in biochemical engineering.
Ms. Bing Liu graduated from Harbin Normal University in 2008
with a Bachelor's Degree in economics. She worked for the Company
in the finance department as assistant to the CFO following her
graduation.
"We greatly appreciate the contributions Ms. Han and Mr. Hao
made to China Sky One Medical. We respect their decisions and wish
them the very best in future," commented Mr. Yan-Qing Liu, Chairman and CEO of China Sky One
Medical. "We are also pleased to have Mr. Li and Mr. Zhang joining
our Board of Directors. Given their substantial industry
experience, I believe they will bring new perspective and insight
to our Board, and make significant contributions in their new
appointments."
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company. The
Company engages in the manufacturing, marketing and distribution of
pharmaceutical, medicinal and diagnostic products. Through its
wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and
Technology Company, Harbin First Bio-Engineering Company Limited,
Heilongjiang Tianlong Pharmaceutical, Inc. and Peng Lai Jin Chuang
Pharmaceutical Company, the Company manufactures and distributes
over-the-counter pharmaceutical products, which make up its major
revenue source. For more information, visit
http://www.cski.com.cn.
Safe Harbor Statement
Certain of the statements made in the press release
constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
can be identified by the use of forward- looking terminology such
as "believe," "expect," "may," "will," "should," "project," "plan,"
"seek," "intend," or "anticipate" or the negative thereof or
comparable terminology. Such statements typically involve risks and
uncertainties and may include financial projections or information
regarding the Company's business development
and change of management team. Actual results could differ
materially from the expectations reflected in such forward-looking
statements as a result of a variety of factors, including the risks
associated with the effect of changing economic conditions in
The People's Republic of China,
variations in cash flow, reliance on collaborative retail partners
and on new product development, variations in new product
development, risks associated with rapid technological change, the
potential of introduced or undetected flaws and defects in
products, consumer acceptance of new products to be launched and
other risk factors detailed in reports filed with the Securities
and Exchange Commission from time to time.
Investor
Relations Contact:
|
|
China Sky
One
Medical
|
CCG Investor
Relations
|
|
Hongyu Pan, CFO
|
David Rudnick
|
|
Email: ir@cski.com.cn
|
Tel:
+1-646-626-4172
|
|
|
Email:
david.rudnick@ccgir.com
|
|
|
Website:
www.ccgirasia.com
|
|
|
|
|
|
Mabel Zhang, Vice
President
|
|
|
Tel:
+1-310-954-1353
|
|
|
Email: mabel.zhang@ccgir.com
|
|
|
|
SOURCE China Sky One Medical, Inc.